Search

Your search keyword '"Alhan, C."' showing total 295 results
Start Over Author "Alhan, C."
295 results on '"Alhan, C."'

1. Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial

Author

van de Loosdrecht, A. A., Cremers, E. M. P., Alhan, C., Duetz, C., in ’t Hout, F. E. M., Visser-Wisselaar, H. A., Chitu, D. A., Verbrugge, A., Cunha, S. M., Ossenkoppele, G. J., Janssen, J. J. W. M., Klein, S. K., Vellenga, E., Huls, G. A., Muus, P., Langemeijer, S. M. C., de Greef, G. E., te Boekhorst, P. A. W., Raaijmakers, M. H. G., van Marwijk Kooy, M., Legdeur, M. C., Wegman, J. J., Deenik, W., de Weerdt, O., van Maanen-Lamme, T. M., Jobse, P., van Kampen, R. J. W., Beeker, A., Wijermans, P. W., Biemond, B. J., Tanis, B. C., van Esser, J. W. J., Schaar, C. G., Noordzij-Nooteboom, H. S., Jacobs, E. M. G., de Graaf, A. O., Jongen-Lavrencic, M., Stevens-Kroef, M. J. P. L., Westers, T. M., and Jansen, J. H.

Published
2024
Full Text
View/download PDF

2. Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes:the HOVON89 trial

Author

van de Loosdrecht, A. A., Cremers, E. M.P., Alhan, C., Duetz, C., in ’t Hout, F. E.M., Visser-Wisselaar, H. A., Chitu, D. A., Verbrugge, A., Cunha, S. M., Ossenkoppele, G. J., Janssen, J. J.W.M., Klein, S. K., Vellenga, E., Huls, G. A., Muus, P., Langemeijer, S. M.C., de Greef, G. E., te Boekhorst, P. A.W., Raaijmakers, M. H.G., van Marwijk Kooy, M., Legdeur, M. C., Wegman, J. J., Deenik, W., de Weerdt, O., van Maanen-Lamme, T. M., Jobse, P., van Kampen, R. J.W., Beeker, A., Wijermans, P. W., Biemond, B. J., Tanis, B. C., van Esser, J. W.J., Schaar, C. G., Noordzij-Nooteboom, H. S., Jacobs, E. M.G., de Graaf, A. O., Jongen-Lavrencic, M., Stevens-Kroef, M. J.P.L., Westers, T. M., Jansen, J. H., van de Loosdrecht, A. A., Cremers, E. M.P., Alhan, C., Duetz, C., in ’t Hout, F. E.M., Visser-Wisselaar, H. A., Chitu, D. A., Verbrugge, A., Cunha, S. M., Ossenkoppele, G. J., Janssen, J. J.W.M., Klein, S. K., Vellenga, E., Huls, G. A., Muus, P., Langemeijer, S. M.C., de Greef, G. E., te Boekhorst, P. A.W., Raaijmakers, M. H.G., van Marwijk Kooy, M., Legdeur, M. C., Wegman, J. J., Deenik, W., de Weerdt, O., van Maanen-Lamme, T. M., Jobse, P., van Kampen, R. J.W., Beeker, A., Wijermans, P. W., Biemond, B. J., Tanis, B. C., van Esser, J. W.J., Schaar, C. G., Noordzij-Nooteboom, H. S., Jacobs, E. M.G., de Graaf, A. O., Jongen-Lavrencic, M., Stevens-Kroef, M. J.P.L., Westers, T. M., and Jansen, J. H.

Abstract

A randomized phase-II study was performed in low/int-1 risk MDS (IPSS) to study efficacy and safety of lenalidomide without (arm A) or with (arm B) ESA/G-CSF. In arm B, patients without erythroid response (HI-E) after 4 cycles received ESA; G-CSF was added if no HI-E was obtained by cycle 9. HI-E served as primary endpoint. Flow cytometry and next-generation sequencing were performed to identify predictors of response. The final evaluation comprised 184 patients; 84% non-del(5q), 16% isolated del(5q); median follow-up: 70.7 months. In arm A and B, 39 and 41% of patients achieved HI-E; median time-to-HI-E: 3.2 months for both arms, median duration of-HI-E: 9.8 months. HI-E was significantly lower in non-del(5q) vs. del(5q): 32% vs. 80%. The same accounted for transfusion independency-at-week 24 (16% vs. 67%), but similar in both arms. Apart from presence of del(5q), high percentages of bone marrow lymphocytes and progenitor B-cells, a low number of mutations, absence of ring sideroblasts, and SF3B1 mutations predicted HI-E. In conclusion, lenalidomide induced HI-E in patients with non-del(5q) and del(5q) MDS without additional effect of ESA/G-CSF. The identified predictors of response may guide application of lenalidomide in lower-risk MDS in the era of precision medicine. (EudraCT 2008-002195-10).

Published
2024

3. Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNet

Author

van der Velden, VHJ, Preijers, F, Johansson, U, Westers, TM, Dunlop, A, Porwit, A, Bene, MC, Valent, P, te Marvelde, J, Wagner-Ballon, O, Oelschlaegel, U, Saft, L, Kordasti, S, Ireland, R, Cremers, E, Alhan, C, Duetz, C, Hobo, W, Chapuis, N, Fontenay, M, Bettelheim, P, Eidenshink-Brodersen, L, Font, P, Loken, MR, Matarraz, S, Ogata, K, Orfao, A, Psarra, K, Subira, D, Wells, DA, Della Porta, MG, Burbury, K, Bellos, F, Weiss, E, Kern, W, van de Loosdrecht, A, van der Velden, VHJ, Preijers, F, Johansson, U, Westers, TM, Dunlop, A, Porwit, A, Bene, MC, Valent, P, te Marvelde, J, Wagner-Ballon, O, Oelschlaegel, U, Saft, L, Kordasti, S, Ireland, R, Cremers, E, Alhan, C, Duetz, C, Hobo, W, Chapuis, N, Fontenay, M, Bettelheim, P, Eidenshink-Brodersen, L, Font, P, Loken, MR, Matarraz, S, Ogata, K, Orfao, A, Psarra, K, Subira, D, Wells, DA, Della Porta, MG, Burbury, K, Bellos, F, Weiss, E, Kern, W, and van de Loosdrecht, A

Abstract

BACKGROUND: Flow cytometry (FCM) aids the diagnosis and prognostic stratification of patients with suspected or confirmed myelodysplastic syndrome (MDS). Over the past few years, significant progress has been made in the FCM field concerning technical issues (including software and hardware) and pre-analytical procedures. METHODS: Recommendations are made based on the data and expert discussions generated from 13 yearly meetings of the European LeukemiaNet international MDS Flow working group. RESULTS: We report here on the experiences and recommendations concerning (1) the optimal methods of sample processing and handling, (2) antibody panels and fluorochromes, and (3) current hardware technologies. CONCLUSIONS: These recommendations will support and facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients. Further standardization and harmonization will be required to integrate FCM in MDS diagnostic evaluations in daily practice.

Published
2023

4. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group

Author

Loosdrecht, AA, Kern, W, Porwit, A, Valent, P, Kordasti, S, Cremers, E, Alhan, C, Duetz, C, Dunlop, A, Hobo, W, Preijers, F, Wagner-Ballon, O, Chapuis, N, Fontenay, M, Bettelheim, P, Eidenschink-Brodersen, L, Font, P, Johansson, U, Loken, MR, Marvelde, JG, Matarraz, S, Ogata, K, Oelschlaegel, U, Orfao, A, Psarra, K, Subira, D, Wells, DA, Bene, MC, Della Porta, MG, Burbury, K, Bellos, F, van der Velden, VHJ, Westers, TM, Saft, L, Ireland, R, Loosdrecht, AA, Kern, W, Porwit, A, Valent, P, Kordasti, S, Cremers, E, Alhan, C, Duetz, C, Dunlop, A, Hobo, W, Preijers, F, Wagner-Ballon, O, Chapuis, N, Fontenay, M, Bettelheim, P, Eidenschink-Brodersen, L, Font, P, Johansson, U, Loken, MR, Marvelde, JG, Matarraz, S, Ogata, K, Oelschlaegel, U, Orfao, A, Psarra, K, Subira, D, Wells, DA, Bene, MC, Della Porta, MG, Burbury, K, Bellos, F, van der Velden, VHJ, Westers, TM, Saft, L, and Ireland, R

Abstract

This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients.

Published
2023

5. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group.

Author

Loosdrecht, A.A. van de, Kern, W., Porwit, A., Valent, P., Kordasti, S., Cremers, E., Alhan, C., Duetz, C., Dunlop, A., Hobo, W.A., Preijers, F.W., Wagner-Ballon, O., Chapuis, N., Fontenay, M., Bettelheim, P., Eidenschink-Brodersen, L., Font, P., Johansson, U., Loken, M.R., Marvelde, J.G. Te, Matarraz, S., Ogata, K., Oelschlaegel, U., Orfao, A., Psarra, K., Subirá, D., Wells, D.A., Béné, M.C., Porta, M.G. Della, Burbury, K., Bellos, F., Velden, V.H. van der, Westers, Theresia M., Saft, L., Ireland, R., Loosdrecht, A.A. van de, Kern, W., Porwit, A., Valent, P., Kordasti, S., Cremers, E., Alhan, C., Duetz, C., Dunlop, A., Hobo, W.A., Preijers, F.W., Wagner-Ballon, O., Chapuis, N., Fontenay, M., Bettelheim, P., Eidenschink-Brodersen, L., Font, P., Johansson, U., Loken, M.R., Marvelde, J.G. Te, Matarraz, S., Ogata, K., Oelschlaegel, U., Orfao, A., Psarra, K., Subirá, D., Wells, D.A., Béné, M.C., Porta, M.G. Della, Burbury, K., Bellos, F., Velden, V.H. van der, Westers, Theresia M., Saft, L., and Ireland, R.

Abstract

01 januari 2023, Item does not contain fulltext, This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients.

Published
2023

6. Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNet.

Author

Velden, V.H. van der, Preijers, F.W., Johansson, U., Westers, Theresia M., Dunlop, A., Porwit, A., Béné, M.C., Valent, P., Marvelde, J. Te, Wagner-Ballon, O., Oelschlaegel, U., Saft, L., Kordasti, S., Ireland, R., Cremers, E., Alhan, C., Duetz, C., Hobo, W.A., Chapuis, N., Fontenay, M., Bettelheim, P., Eidenshink-Brodersen, L., Font, P., Loken, M.R., Matarraz, S., Ogata, K., Orfao, A., Psarra, K., Subirá, D., Wells, D.A., Porta, M.G. Della, Burbury, K., Bellos, F., Weiß, E., Kern, W., Loosdrecht, A. van de, Velden, V.H. van der, Preijers, F.W., Johansson, U., Westers, Theresia M., Dunlop, A., Porwit, A., Béné, M.C., Valent, P., Marvelde, J. Te, Wagner-Ballon, O., Oelschlaegel, U., Saft, L., Kordasti, S., Ireland, R., Cremers, E., Alhan, C., Duetz, C., Hobo, W.A., Chapuis, N., Fontenay, M., Bettelheim, P., Eidenshink-Brodersen, L., Font, P., Loken, M.R., Matarraz, S., Ogata, K., Orfao, A., Psarra, K., Subirá, D., Wells, D.A., Porta, M.G. Della, Burbury, K., Bellos, F., Weiß, E., Kern, W., and Loosdrecht, A. van de

Abstract

01 januari 2023, Item does not contain fulltext, BACKGROUND: Flow cytometry (FCM) aids the diagnosis and prognostic stratification of patients with suspected or confirmed myelodysplastic syndrome (MDS). Over the past few years, significant progress has been made in the FCM field concerning technical issues (including software and hardware) and pre-analytical procedures. METHODS: Recommendations are made based on the data and expert discussions generated from 13 yearly meetings of the European LeukemiaNet international MDS Flow working group. RESULTS: We report here on the experiences and recommendations concerning (1) the optimal methods of sample processing and handling, (2) antibody panels and fluorochromes, and (3) current hardware technologies. CONCLUSIONS: These recommendations will support and facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients. Further standardization and harmonization will be required to integrate FCM in MDS diagnostic evaluations in daily practice.

Published
2023

7. Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group.

Author

Porwit, A., Béné, M.C., Duetz, C., Matarraz, S., Oelschlaegel, U., Westers, Theresia M., Wagner-Ballon, O., Kordasti, S., Valent, P., Preijers, F.W., Alhan, C., Bellos, F., Bettelheim, P., Burbury, K., Chapuis, N., Cremers, E., Porta, M.G. Della, Dunlop, A., Eidenschink-Brodersen, L., Font, P., Fontenay, M., Hobo, W., Ireland, R., Johansson, U., Loken, M.R., Ogata, K., Orfao, A., Psarra, K., Saft, L., Subira, D., Marvelde, J. Te, Wells, D.A., Velden, V.H. van der, Kern, W., Loosdrecht, A.A. van de, Porwit, A., Béné, M.C., Duetz, C., Matarraz, S., Oelschlaegel, U., Westers, Theresia M., Wagner-Ballon, O., Kordasti, S., Valent, P., Preijers, F.W., Alhan, C., Bellos, F., Bettelheim, P., Burbury, K., Chapuis, N., Cremers, E., Porta, M.G. Della, Dunlop, A., Eidenschink-Brodersen, L., Font, P., Fontenay, M., Hobo, W., Ireland, R., Johansson, U., Loken, M.R., Ogata, K., Orfao, A., Psarra, K., Saft, L., Subira, D., Marvelde, J. Te, Wells, D.A., Velden, V.H. van der, Kern, W., and Loosdrecht, A.A. van de

Abstract

01 januari 2023, Item does not contain fulltext, Multiparameter flow cytometry (MFC) is one of the essential ancillary methods in bone marrow (BM) investigation of patients with cytopenia and suspected myelodysplastic syndrome (MDS). MFC can also be applied in the follow-up of MDS patients undergoing treatment. This document summarizes recommendations from the International/European Leukemia Net Working Group for Flow Cytometry in Myelodysplastic Syndromes (ELN iMDS Flow) on the analytical issues in MFC for the diagnostic work-up of MDS. Recommendations for the analysis of several BM cell subsets such as myeloid precursors, maturing granulocytic and monocytic components and erythropoiesis are given. A core set of 17 markers identified as independently related to a cytomorphologic diagnosis of myelodysplasia is suggested as mandatory for MFC evaluation of BM in a patient with cytopenia. A myeloid precursor cell (CD34(+) CD19(-) ) count >3% should be considered immunophenotypically indicative of myelodysplasia. However, MFC results should always be evaluated as part of an integrated hematopathology work-up. Looking forward, several machine-learning-based analytical tools of interest should be applied in parallel to conventional analytical methods to investigate their usefulness in integrated diagnostics, risk stratification, and potentially even in the evaluation of response to therapy, based on MFC data. In addition, compiling large uniform datasets is desirable, as most of the machine-learning-based methods tend to perform better with larger numbers of investigated samples, especially in such a heterogeneous disease as MDS.

Published
2023

12. Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)-mutant myelodysplastic syndromes subtype

Author

Duetz, C., Westers, T.M., Hout, F.E.M. In 't, Cremers, E.M., Alhan, C., Venniker-Punt, B., Visser-Wisselaar, H.A., Chitu, Dana A., Graaf, A.O. de, Smit, L., Jansen, J.H., Loosdrecht, A.A. van de, Duetz, C., Westers, T.M., Hout, F.E.M. In 't, Cremers, E.M., Alhan, C., Venniker-Punt, B., Visser-Wisselaar, H.A., Chitu, Dana A., Graaf, A.O. de, Smit, L., Jansen, J.H., and Loosdrecht, A.A. van de

Abstract

Contains fulltext : 235747.pdf (Publisher’s version ) (Open Access)

Published
2021

13. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group

Author

Westers, T M, Ireland, R, Kern, W, Alhan, C, Balleisen, J S, Bettelheim, P, Burbury, K, Cullen, M, Cutler, J A, Della Porta, M G, Dräger, A M, Feuillard, J, Font, P, Germing, U, Haase, D, Johansson, U, Kordasti, S, Loken, M R, Malcovati, L, te Marvelde, J G, Matarraz, S, Milne, T, Moshaver, B, Mufti, G J, Ogata, K, Orfao, A, Porwit, A, Psarra, K, Richards, S J, Subirá, D, Tindell, V, Vallespi, T, Valent, P, van der Velden, V H J, de Witte, T M, Wells, D A, Zettl, F, Béné, M C, and van de Loosdrecht, A A

Published
2012
Full Text
View/download PDF

17. Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial

Author

Stevens-Kroef, M.J.P.L., Olde Weghuis, D.E.M., Elidrissi-Zaynoun, N., Reijden, B.A. van der, Cremers, E.M., Alhan, C., Westers, T.M., Visser-Wisselaar, H.A., Chitu, D.A., Cunha, S.M., Vellenga, E., Klein, S.K., Wijermans, P., Greef, G.E. de, Schaafsma, M.R., Muus, P., Ossenkoppele, G.J., Loosdrecht, A.A. van de, Jansen, J.H., Hematology, AGEM - Digestive immunity, Internal medicine, CCA - Cancer biology and immunology, Hematology laboratory, Guided Treatment in Optimal Selected Cancer Patients (GUTS), and Stem Cell Aging Leukemia and Lymphoma (SALL)

Subjects
SCORING SYSTEM, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], Tumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14], WORLD-HEALTH-ORGANIZATION, ACUTE MYELOID-LEUKEMIA, HIGH-RISK MDS, PERIPHERAL-BLOOD, HEMATOLOGICAL MALIGNANCIES, UNIPARENTAL DISOMY, SNP-ARRAY, CHROMOSOMAL LESIONS, COPY NUMBER ALTERATIONS
Abstract

Karyotyping is considered as the gold standard in the genetic subclassification of myelodysplastic syndrome (MDS). Oligo/SNP-based genomic array profiling is a high-resolution tool that also enables genome wide analysis. We compared karyotyping with oligo/SNP-based array profiling in 104 MDS patients from the HOVON-89 study. Oligo/SNP-array identified all cytogenetically defined genomic lesions, except for subclones in two cases and balanced translocations in three cases. Conversely, oligo/SNP-based genomic array profiling had a higher success rate, showing 55 abnormal cases, while an abnormal karyotype was found in only 35 patients. In nine patients whose karyotyping was unsuccessful because of insufficient metaphases or failure, oligo/SNP-based array analysis was successful. Based on cytogenetic visible abnormalities as identified by oligo/SNP-based genomic array prognostic scores based on IPSS/-R were assigned. These prognostic scores were identical to the IPSS/-R scores as obtained with karyotyping in 95%-96% of the patients. In addition to the detection of cytogenetically defined lesions, oligo/SNP-based genomic profiling identified focal copy number abnormalities or regions of copy neutral loss of heterozygosity that were out of the scope of karyotyping and fluorescence in situ hybridization. Of interest, in 26 patients we demonstrated such cytogenetic invisible abnormalities. These abnormalities often involved regions that are recurrently affected in hematological malignancies, and may therefore be of clinical relevance. Our findings indicate that oligo/SNP-based genomic array can be used to identify the vast majority of recurrent cytogenetic abnormalities in MDS. Furthermore, oligo/SNP-based array profiling yields additional genetic abnormalities that may be of clinical importance.

Published
2017

18. Behavior Of Base-Isolated Liquid Storage Tanks Under Synthetic Near-Fault Earthquake Pulses

Author

Alhan, C., Güler, E., Hatice Gazi, Internal medicine, and AGEM - Digestive immunity

Abstract

Protection of liquid storage tanks from earthquake hazards is vital as damaging of these structures may result in significant economic losses. Base isolation has emerged as a successful alternative to classical earthquake resistant design of liquid storage tanks. However, near-fault earthquake records may include velocity pulses with long periods and large amplitudes that may cause large seismic responses since the isolation periods of base-isolated liquid storage tanks encompass a similar range with pulse periods of near-fault earthquakes. In order to assess the influence of near-fault earthquakes on the seismic response parameters, here, the behavior of a benchmark base-isolated liquid storage tank is evaluated under synthetically generated pulses which represent near-fault earthquakes of different magnitudes recorded at different fault-distances. Seismic response parameters including base and sloshing fluid displacements, isolation system shear, fluidtank shear force, and fluid shear force are reported in a comparative manner.

Published
2017

24. Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes

Author

Cremers, E.M., Westers, T.M., Alhan, C., Cali, C., Visser-Wisselaar, H.A., Chitu, D.A., Velden, V.H. van der, Marvelde, J.G. Te, Klein, S.K., Muus, P., Vellenga, E., Greef, G.E. de, Legdeur, M.C., Wijermans, P.W., Stevens-Kroef, M.J.P.L., Silva-Coelho, P., Jansen, J.H., Ossenkoppele, G.J., Loosdrecht, A.A. van de, Cremers, E.M., Westers, T.M., Alhan, C., Cali, C., Visser-Wisselaar, H.A., Chitu, D.A., Velden, V.H. van der, Marvelde, J.G. Te, Klein, S.K., Muus, P., Vellenga, E., Greef, G.E. de, Legdeur, M.C., Wijermans, P.W., Stevens-Kroef, M.J.P.L., Silva-Coelho, P., Jansen, J.H., Ossenkoppele, G.J., and Loosdrecht, A.A. van de

Abstract

Contains fulltext : 169708.pdf (publisher's version ) (Open Access), Flow cytometric analysis is a recommended tool in the diagnosis of myelodysplastic syndromes. Current flow cytometric approaches evaluate the (im)mature myelo-/monocytic lineage with a median sensitivity and specificity of ~71% and ~93%, respectively. We hypothesized that the addition of erythroid lineage analysis could increase the sensitivity of flow cytometry. Hereto, we validated the analysis of erythroid lineage parameters recommended by the International/European LeukemiaNet Working Group for Flow Cytometry in Myelodysplastic Syndromes, and incorporated this evaluation in currently applied flow cytometric models. One hundred and sixty-seven bone marrow aspirates were analyzed; 106 patients with myelodysplastic syndromes, and 61 cytopenic controls. There was a strong correlation between presence of erythroid aberrancies assessed by flow cytometry and the diagnosis of myelodysplastic syndromes when validating the previously described erythroid evaluation. Furthermore, addition of erythroid aberrancies to two different flow cytometric models led to an increased sensitivity in detecting myelodysplastic syndromes: from 74% to 86% for the addition to the diagnostic score designed by Ogata and colleagues, and from 69% to 80% for the addition to the integrated flow cytometric score for myelodysplastic syndromes, designed by our group. In both models the specificity was unaffected. The high sensitivity and specificity of flow cytometry in the detection of myelodysplastic syndromes illustrates the important value of flow cytometry in a standardized diagnostic approach. The trial is registered at www.trialregister.nl as NTR1825; EudraCT n.: 2008-002195-10.

Published
2017

25. Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes

Author

Cremers, EMP, Westers, TM, Alhan, C, Cali, C, Visser - Wisselaar, Heleen, Chitu, Dana, van der Velden, Vincent, te Marvelde, Jeroen, Klein, SK, Muus, P, Vellenga, E, Greef, Georgine, Legdeur, M, Wijermans, PW, Stevens-Kroef, M, da Silva-Coelho, P, Jansen, JH, Ossenkoppele, GJ, van de Loosdrecht, AA, Cremers, EMP, Westers, TM, Alhan, C, Cali, C, Visser - Wisselaar, Heleen, Chitu, Dana, van der Velden, Vincent, te Marvelde, Jeroen, Klein, SK, Muus, P, Vellenga, E, Greef, Georgine, Legdeur, M, Wijermans, PW, Stevens-Kroef, M, da Silva-Coelho, P, Jansen, JH, Ossenkoppele, GJ, and van de Loosdrecht, AA

Published
2017

27. Good’s syndrome:An uncommon cause of therapy-resistant diarrhoea

Author

Disselhorst, M. J., Dickhoff, C., Alhan, C., Pulmonary medicine, Cardio-thoracic surgery, CCA - Clinical Therapy Development, ICaR - Ischemia and repair, and Internal medicine

Abstract

Diarrhoea is a common symptom for which the aetiology will be straightforward in many cases. However, when a common aetiology is not found, the wide variety of other options can feel like finding a needle in a haystack. In this case report, we describe a patient who was referred to our centre with therapy-resistant, secretory diarrhoea, which was the presenting symptom of Good’s syndrome, a rare form of adult-onset immunodeficiency associated with thymoma. The conclusions from this case report give direction for ‘finding the needle’ and contribute to a focused approach to patients who present with therapy-resistant diarrhoea.

Published
2016

29. Implementation of flow cytometry in the diagnostic work-up of myelodysplastic syndromes in a multicenter approach

Author

Westers, T.M., Velden, V.H. van der, Alhan, C., Bekkema, R., Bijkerk, A., Brooimans, R.A., Cali, C., Drager, A.M., de Haas, V., Homburg, C., de Jong, A., Kuiper-Kramer, P.E., Leenders, M., Lommerse, I., Marvelde, J.G. Te, van der Molen-Sinke, J.K., Moshaver, B., Mulder, A.B., Preijers, F.W.M.B., Schindhelm, R.K., van der Sluijs, A., van Wering, E.R., Westra, A.H., Loosdrecht, A.A. van de, Working Party on Flow Cytometry in, M.D.S.o.D.S.o.C., Hematology laboratory, Pediatric surgery, Hematology, and CCA - Disease profiling

Subjects
Male, Oncology, BLASTS, Cancer Research, medicine.medical_specialty, Multicenter analysis, Concordance, BONE-MARROW, Cell Separation, Bioinformatics, Flow cytometry, Translational research [ONCOL 3], Internal medicine, hemic and lymphatic diseases, Diagnosis, medicine, MDS, Humans, Aged, Netherlands, Aged, 80 and over, PHENOTYPIC FEATURES, UTILITY, medicine.diagnostic_test, Guideline adherence, business.industry, Myelodysplastic syndromes, Hematology, medicine.disease, List mode, CYTOGENETICS, Work-up, Standardization, DIFFERENTIATION, Multicenter study, Myelodysplastic Syndromes, Implementation, Practice Guidelines as Topic, CELLS, Female, Guideline Adherence, business, Pitfalls
Abstract

Flow cytometry (FC) is recognized as an important tool in the diagnosis of myelodysplastic syndromes (MDS) especially when standard criteria fail. A working group within the Dutch Society of Cytometry aimed to implement FC in the diagnostic work-up of MDS. Hereto, guidelines for data acquisition, analysis and interpretation were formulated. Based on discussions on analyses of list mode data files and fresh MDS bone marrow samples and recent literature, the guidelines were modified. Over the years (2005-2011), the concordance between the participating centers increased indicating that the proposed guidelines contributed to a more objective, standardized FC analysis, thereby ratifying the implementation of FC in MDS. (C) 2011 Elsevier Ltd. All rights reserved.

Published
2012

35. Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes

Author

Cremers, E.M.P. (Eline), Westers, T.M. (Theresia), Alhan, C. (Canan), Cali, C. (Claudia), Visser-Wisselaar, H. (Heleen), Chitu, D.A. (Dana), Velden, V.H.J. (Vincent) van der, Marvelde, J.G. (Jeroen) te, Klein, S.K. (Saskia K.), Muus, P. (P.), Vellenga, E. (Edo), Greef, G.E. (Georgine) de, Legdeur, M.C.J.C. (M. C J C), Wijermans, P.W. (Pierre), Stevens-Kroef, M. (Marian), da Silva-Coelho, P. (Pedro), Jansen, J.H. (Joop H.), Ossenkoppele, G.J. (Gert), Loosdrecht, A.A. (Arjan) van de, Cremers, E.M.P. (Eline), Westers, T.M. (Theresia), Alhan, C. (Canan), Cali, C. (Claudia), Visser-Wisselaar, H. (Heleen), Chitu, D.A. (Dana), Velden, V.H.J. (Vincent) van der, Marvelde, J.G. (Jeroen) te, Klein, S.K. (Saskia K.), Muus, P. (P.), Vellenga, E. (Edo), Greef, G.E. (Georgine) de, Legdeur, M.C.J.C. (M. C J C), Wijermans, P.W. (Pierre), Stevens-Kroef, M. (Marian), da Silva-Coelho, P. (Pedro), Jansen, J.H. (Joop H.), Ossenkoppele, G.J. (Gert), and Loosdrecht, A.A. (Arjan) van de

Abstract

Flow cytometric analysis is a recommended tool in the diagnosis of myelodysplastic syndromes. Current flow cytometric approaches evaluate the (im)mature myelo-/monocytic lineage with a median sensitivity and specificity of ~71% and ~93%, respectively. We hypothesized that the addition of erythroid lineage analysis could increase the sensitivity of flow cytometry. Hereto, we validated the analysis of erythroid lineage parameters recommended by the International/European LeukemiaNet Working Group for Flow Cytometry in Myelodysplastic Syndromes, and incorporated this evaluation in currently applied flow cytometric models. One hundred and sixty-seven bone marrow aspirates w

Published
2016
Full Text
View/download PDF

36. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes

Author

Alhan, C., Westers, T.M., Helm, L.H. van der, Eeltink, C., Huls, G.A., Witte, B.I., Buchi, F., Santini, V., Ossenkoppele, G.J., Loosdrecht, A.A. van de, Hematology laboratory, Hematology, Epidemiology and Data Science, and CCA - Disease profiling

Subjects
Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], hemic and lymphatic diseases
Abstract

Item does not contain fulltext BACKGROUND: In intermediate-2 (Int-2) and high risk patients with myelodysplastic syndromes (MDS), treatment with azacitidine is associated with hematological improvement and prolonged overall survival (OS) in patients who respond to therapy. However, only half of the patients who are treated will benefit from this treatment. It is a major challenge to predict which patients are likely to respond to treatment. The aim of this study was to investigate the predictive value of immunophenotyping for response to treatment with azacitidine of Int-2 and high risk MDS patients. METHODS: Bone marrow aspirates were analyzed by flow cytometry in 42 patients with Int-2 and high risk MDS, chronic myelomonocytic leukemia, or low blast count acute myeloid leukemia before treatment and after every third cycle of azacitidine. A flow score was calculated using the flow cytometric scoring system (FCSS). RESULTS: The presence of myeloid progenitors with an aberrant immunophenotype was significantly associated with lack of response (p = 0.02). A low pretreatment FCSS was associated with significantly better OS compared with a high pretreatment FCSS (p = 0.03). A significant decrease in FCSS was observed in patients with complete response after three cycles azacitidine compared to patients with progressive disease (p = 0.006). CONCLUSIONS: Absence of aberrant myeloid progenitor cells at baseline and/or a decrease in the FCSS during treatment identified Int-2 and high risk MDS patients who are likely to respond to treatment with azacitidine.

Published
2014

40. 62 MUTATIONS IN EPIGENETIC REGULATORS ARE SIGNIFICANTLY ASSOCIATED WITH ABERRANT EXPRESSION OF MYELOID DIFFERENTIATION ANTIGENS ON MYELOID PROGENITOR CELLS IN LOW/INTERMEDIATE RISK MDS

Author

Coelho, P. Silva, primary, Cremers, E.M.P., additional, Westers, T.M., additional, de Graaf, A.O., additional, Alhan, C., additional, Cali, C., additional, Visser-Wisselaar, H.A., additional, Chitu, D.A., additional, Vellenga, E., additional, Klein, S.K., additional, Wijermans, P.W., additional, de Greef, G.E., additional, Legdeur, M.C., additional, Muus, P., additional, Ossenkoppele, G.J., additional, Stevens-Kroef, M.J.P.L., additional, van der Reijden, B., additional, Jansen, J.H., additional, and van de Loosdrecht, A.A., additional

Published
2015
Full Text
View/download PDF

42. Congenital intrapericardial left atrial appendage aneurysm

Author

Yaliniz H., Salih O.K., Alhan C., Gocen U., Tokcan A., and Çukurova Üniversitesi

Subjects
Adult, Male, Cardiopulmonary Bypass, Heart atria, Stroke, Diagnosis, Differential, Echocardiography, cardiovascular system, Humans, Atrial Appendage, Radiography, Thoracic, cardiovascular diseases, Cardiac Surgical Procedures, Heart Aneurysm, Aneurysms, Pericardium, Arrhythmia
Abstract

PubMedID: 17308530 Congenital true aneurysms of left atrial appendage are very rare. Abnormal cardiac silhouette on the chest roentgenograph is usually an important clue for the diagnosis. They are commonly associated with supraventricular arrhythmias and life-threatening systemic embolization. We report here the surgically-corrected case of a patient with congenital left atrial appendage aneurysm.

Published
2007

46. Robotic mitral valve replacement

Author

Senay, S., primary, Gullu, A. U., additional, Kocyigit, M., additional, Degirmencioglu, A., additional, Karabulut, H., additional, and Alhan, C., additional

Published
2014
Full Text
View/download PDF

48. Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts.

Author

Helm, L.H. van der, Veeger, N.J., Kooy, M.v., Beeker, A., Weerdt, O. de, Groot, M. de, Alhan, C., Hoogendoorn, M., Laterveer, L., Loosdrecht, A.A. van de, Koedam, J., Vellenga, E., Huls, G.A., Helm, L.H. van der, Veeger, N.J., Kooy, M.v., Beeker, A., Weerdt, O. de, Groot, M. de, Alhan, C., Hoogendoorn, M., Laterveer, L., Loosdrecht, A.A. van de, Koedam, J., Vellenga, E., and Huls, G.A.

Abstract

1 augustus 2013, Item does not contain fulltext, The efficacy of azacitidine has been demonstrated in acute myeloid leukemia (AML) patients with 20-30% bone marrow (BM) blasts, but limited data is available on patients with >/=30% blasts. We analyzed 55 newly diagnosed AML patients, treated with azacitidine. The overall response rate was 42%. Median overall survival (OS) was 12.3 months. We confirmed poor-risk cytogenetics, therapy-related AML, performance score >/=2, and white blood cell count >/=15x10(9)/L as independent adverse predictors for OS. The BM blast percentage, however, had no impact on OS (P=0.55). In conclusion, administration of azacitidine is effective in AML patients with 20-30% and >30% BM blasts.

Published
2013

49. Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group

Author

Loosdrecht, A.A. van de, Ireland, R., Kern, W., Della Porta, M.G., Alhan, C., Balleisen, J.S., Bettelheim, P., Bowen, D.T., Burbury, K., Eidenschink, L., Cazzola, M., Chu, S.S., Cullen, M., Cutler, J.A., Drager, A.M., Feuillard, J., Fenaux, P., Font, P., Germing, U., Haase, D., Hellstrom-Lindberg, E., Johansson, U., Kordasti, S., Loken, M.R., Malcovati, L., Marvelde, J.G. Te, Matarraz, S., Milne, T., Moshaver, B., Mufti, G.J., Nikolova, V., Ogata, K., Oelschlaegel, U., Orfao, A., Ossenkoppele, G.J., Porwit, A., Platzbecker, U., Preijers, F.W.M.B., Psarra, K., Richards, S.J., Subira, D., Seymour, J.F., Tindell, V., Vallespi, T., Valent, P., Velden, V.H. van der, Wells, D.A., Witte, T.J.M. de, Zettl, F., Bene, M.C., Westers, T.M., Loosdrecht, A.A. van de, Ireland, R., Kern, W., Della Porta, M.G., Alhan, C., Balleisen, J.S., Bettelheim, P., Bowen, D.T., Burbury, K., Eidenschink, L., Cazzola, M., Chu, S.S., Cullen, M., Cutler, J.A., Drager, A.M., Feuillard, J., Fenaux, P., Font, P., Germing, U., Haase, D., Hellstrom-Lindberg, E., Johansson, U., Kordasti, S., Loken, M.R., Malcovati, L., Marvelde, J.G. Te, Matarraz, S., Milne, T., Moshaver, B., Mufti, G.J., Nikolova, V., Ogata, K., Oelschlaegel, U., Orfao, A., Ossenkoppele, G.J., Porwit, A., Platzbecker, U., Preijers, F.W.M.B., Psarra, K., Richards, S.J., Subira, D., Seymour, J.F., Tindell, V., Vallespi, T., Valent, P., Velden, V.H. van der, Wells, D.A., Witte, T.J.M. de, Zettl, F., Bene, M.C., and Westers, T.M.

Abstract

Item does not contain fulltext, An international working group within the European LeukemiaNet gathered, aiming to determine the role of flow cytometry (FC) in myelodysplastic syndromes (MDS). It was agreed that FC has a substantial application in disease characterization, diagnosis and prognosis. FC may also be useful in predicting treatment responses and monitoring novel and standard therapeutic regimens. In this article the rationale is discussed that flow cytometry should be integrated as a part of diagnostic and prognostic scoring systems in MDS.

Published
2013

50. Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program.

Author

Abouyahya, I., Alhan, C., Westers, T.M., Boekhorst, P.A.W., Kappers-Klunne, M.C., Coenen, J.L., Heyning, F.H., Huls, G.A., Wolf, J.T. de, Imholz, A.L., Koene, H.R., Veth, G., Kruijf, E.J. de, Muus, P., Planken, E.V., Segeren, C.M., Vasmel, W.L., Velden, A.M. van der, Velders, G.A., Koedam, J., Ossenkoppele, G.J., Loosdrecht, A.A. van de, Abouyahya, I., Alhan, C., Westers, T.M., Boekhorst, P.A.W., Kappers-Klunne, M.C., Coenen, J.L., Heyning, F.H., Huls, G.A., Wolf, J.T. de, Imholz, A.L., Koene, H.R., Veth, G., Kruijf, E.J. de, Muus, P., Planken, E.V., Segeren, C.M., Vasmel, W.L., Velden, A.M. van der, Velders, G.A., Koedam, J., Ossenkoppele, G.J., and Loosdrecht, A.A. van de

Abstract

01 april 2013, Item does not contain fulltext

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results